Leuven,
Tom has over 25 years’ experience in senior finance, strategy and operational roles including capital raising, accounting, and audit. He most recently served as CFO at Generation Bio (NASDAQ: GBIO), a non-viral gene therapy company based in
Prior to joining Generation Bio, Tom was Senior Vice President (SVP) and CFO at Vertex Pharmaceuticals (NASDAQ: VRTX), one of the world’s most highly valued biotech companies, with a multi-billion-dollar turnover. At Vertex Tom was responsible for financial strategy and operations including finance, accounting, and internal audit functions.
Prior to Vertex, he was the CFO and SVP of Finance and Corporate Strategy at Ironwood Pharmaceuticals (NASDAQ: IRWD), a GI-focused healthcare company. Before joining Ironwood, Tom spent 20 years with Johnson & Johnson, serving in various roles in the US and abroad, including being Worldwide VP of Finance and CFO of Ethicon, a major medical device company, and VP and CFO of
Tom is currently on the board of AC Immune SA (NASDAQ: ACIU), a clinical stage Swiss biopharmaceutical company focused on neurodegenerative diseases.
Tom holds a Bachelor of Science degree in accounting from the
“We are delighted to welcome Tom to
On behalf of the Board I would like to take this opportunity to thank Dominique for his contribution to
_
Oxurion Virtual R&D Investor Day to take place on Thursday 15th
Please consult Oxurion’s website for registration and call details, or follow this link:
https://www.investis-live.com/oxurion/5f7c2e6ed33b270c005a4f88/ffdl
END
For further information please contact:
Dr CEO Tel: +32 16 75 13 10 | Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com |
About
·THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1 results for the treatment of DME. The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
THR-149 was developed in conjunction with
·THR-687, is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients.
Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in
THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV (Euronext & NASDAQ: GLPG).
More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
© OMX, source